视频显示终端干眼应用P2Y2受体激动剂治疗的效果观察

Observation on the application of P2Y2 receptor agonists in the treatment of dry eye due to visual display terminal

目的观察视频显示终端干眼(VDT)应用嘌呤受体族中的P2Y2受体的激动剂(地夸磷索钠滴眼液)治疗的效果。方法前瞻性随机对照研究。纳入2020年2月至2020年8月与2021年6月至2021年9月福建省立医院的视频显示终端干眼连续病例60例,年龄(26.05±1.97)岁,随机分为两组:研究组30例予嘌呤受体族中的P2Y2受体的激动剂滴眼,对照组30例未予干预。随访4周进行两组效果对比。结果随访4周,研究组的干眼相关生活质量评分、泪膜破裂时间、角结膜染色评分和泪河高度显著改善,而且优于对照组(均P<0.001);泪液分泌试验及结膜充血评分无明显改善(t=-1.757,1.157;P=0.084,0.252),与对照组相比差异无统计学意义(t=1.478,1.856;P=0.145,0.068);结膜印迹细胞学与基线相比未见明显改变。随访期间,未观察到严重不良反应。结论视频显示终端年轻干眼患者使用P2Y2受体激动剂治疗安全有效。

Objective To observe the efficacy of application of P2Y2 receptor agonists(diquafosol ophthalmic solution)in dry eye due to visual display terminal.Methods This was a prospective randomized controlled study.Sixty patients with dry eye due to visual display terminal in Fujian Provincial Hospital from Feb.2020 to Aug.2020 and from Jun.2021 to Sep.2021 were consecutively included and randomly divided into two groups.The age of the patients were(26.05±1.97)years.The 30 cases of the study group was given P2Y2 receptor agonists eye drops and the 30 cases of the control group were not given any treatment.The patients were followed up for 4 weeks and the efficacy between the two groups were compared.Results At 4 weeks of follow-up,dry eye-related quality-of-life score,tear film break-up time,keratoconjunctival staining scores and tear meniscus height were significantly improved in the study group,and which were superior to those of the control group(all P<0.001).Schirmer I test and conjunctival hyperemia scores in the study group were not significantly improved(t=-1.757,1.157;P=0.084,0.252),with no statistically significant difference compared to the control group(t=1.478,1.856;P=0.145,0.068).No significant change in conjunctival impression cytology compared to baseline.During the follow-up period,no serious adverse reaction was observed.Conclusion Application of P2Y2 receptor agonists for young patients with dry eye due to visual display terminal are safe and effective.